Daily Medication Pearl: Semaglutide (Wegovy)

Semaglutide (Wegovy) is indicated in addition to a calorie restricted diet and increased physical activity for chronic weight management in adult patients.

Pearl of the day medication: Semaglutide (Wegovy)

Indication: Semaglutide (Wegovy) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a restricted calorie diet and increased physical activity for chronic weight management in adult patients with a body mass index initial body weight of 30 kg/m2 or more (obesity).

Insight:

  • Dosage: Start at 0.25 mg once a week for 4 weeks. Every 4 weeks, increase the dose until you reach a dose of 2.4 mg.
  • Dosage forms: Injection of a single-dose pre-filled pen that delivers doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg.
  • Adverse events: The most common adverse reactions reported in 5% or more of semaglutide-treated patients are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension , belching, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis and gastroesophageal reflux disease.
  • Action mechanism: Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds and activates the GLP-1 receptor, the target of native GLP-1.

Source: (fda.gov)

Comments are closed.